{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["49(13)"],"submitter":["Ruigrok EAM"],"funding":["Advanced Accelerator Applications"],"pubmed_abstract":["<h4>Purpose</h4>The radiolabeled gastrin-releasing peptide receptor (GRPR)-targeting antagonist NeoB is a promising radioligand for imaging and therapy of GRPR-expressing malignancies. In the current study, we aimed to discover the target organs of toxicity and the radiotoxic effects to these organs, when repeated dosages of [<sup>177</sup>Lu]Lu-NeoB are administered to healthy female and male mice.<h4>Methods</h4>Animals received either 3 injections, with a 7-day interval, of vehicle (control group 1), 1200 pmol [<sup>175</sup>Lu]Lu-NeoB (control group 2) or 40 MBq/400 pmol, 80 MBq/800 pmol, and 120 MBq/1200 pmol [<sup>177</sup>Lu]Lu-NeoB (treatment groups 1, 2, and 3, respectively). At week 5, 19, and 43 after the first injection acute, early, and late organ toxicity, respectively, was d"],"journal":["European journal of nuclear medicine and molecular imaging"],"pagination":["4440-4451"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9605926"],"repository":["biostudies-literature"],"pubmed_title":["Safety of [<sup>177</sup>Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity."],"pmcid":["PMC9605926"],"pubmed_authors":["de Jong M","Dalm SU","Konijnenberg MW","Rolfo K","Stuurman DC","de Blois E","Verhoeven M","de Ridder CMA","Bertarione L","Ruigrok EAM"],"additional_accession":[]},"is_claimable":false,"name":"Safety of [<sup>177</sup>Lu]Lu-NeoB treatment: a preclinical study characterizing absorbed dose and acute, early, and late organ toxicity.","description":"<h4>Purpose</h4>The radiolabeled gastrin-releasing peptide receptor (GRPR)-targeting antagonist NeoB is a promising radioligand for imaging and therapy of GRPR-expressing malignancies. In the current study, we aimed to discover the target organs of toxicity and the radiotoxic effects to these organs, when repeated dosages of [<sup>177</sup>Lu]Lu-NeoB are administered to healthy female and male mice.<h4>Methods</h4>Animals received either 3 injections, with a 7-day interval, of vehicle (control group 1), 1200 pmol [<sup>175</sup>Lu]Lu-NeoB (control group 2) or 40 MBq/400 pmol, 80 MBq/800 pmol, and 120 MBq/1200 pmol [<sup>177</sup>Lu]Lu-NeoB (treatment groups 1, 2, and 3, respectively). At week 5, 19, and 43 after the first injection acute, early, and late organ toxicity, respectively, was d","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-19T18:52:47.37Z","creation":"2024-12-04T08:52:39.04Z"},"accession":"S-EPMC9605926","cross_references":{"pubmed":["35951084"],"doi":["10.1007/s00259-022-05926-2"]}}